Liisa Bayko
Stock Analyst at Evercore ISI Group
(3.64)
# 824
Out of 5,113 analysts
78
Total ratings
56.92%
Success rate
26.54%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Liisa Bayko
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals | Maintains: Outperform | $475 → $530 | $474.17 | +11.77% | 20 | Jan 23, 2026 | |
| ENTA Enanta Pharmaceuticals | Maintains: Outperform | $20 → $12 | $12.98 | -7.55% | 5 | Sep 15, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $280 → $515 | $354.75 | +45.19% | 2 | Sep 11, 2025 | |
| SVRA Savara | Maintains: In-Line | $3 → $2 | $5.85 | -65.81% | 5 | May 28, 2025 | |
| CRSP CRISPR Therapeutics AG | Upgrades: Outperform | $60 → $99 | $54.26 | +82.45% | 2 | Feb 14, 2025 | |
| TVTX Travere Therapeutics | Maintains: Outperform | $33 → $45 | $30.03 | +49.85% | 5 | Feb 12, 2025 | |
| BCRX BioCryst Pharmaceuticals | Maintains: Outperform | $10 → $12 | $6.76 | +77.51% | 5 | Jan 13, 2025 | |
| EDIT Editas Medicine | Maintains: Outperform | $7 → $5 | $2.11 | +136.97% | 5 | Dec 16, 2024 | |
| KNSA Kiniksa Pharmaceuticals International, | Maintains: Outperform | $30 → $35 | $44.64 | -21.59% | 4 | Oct 30, 2024 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Outperform | $405 → $360 | $500.39 | -28.06% | 9 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $7 → $2 | $1.21 | +65.98% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $60 → $80 | $24.62 | +224.94% | 8 | Jun 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $25 | $6.18 | +304.53% | 1 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $35 | $5.66 | +518.37% | 1 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $24 | $46.75 | -48.66% | 1 | Jun 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $30 | $19.82 | +51.36% | 1 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Outperform | $10 | $4.16 | +140.38% | 1 | Feb 5, 2020 |
Vertex Pharmaceuticals
Jan 23, 2026
Maintains: Outperform
Price Target: $475 → $530
Current: $474.17
Upside: +11.77%
Enanta Pharmaceuticals
Sep 15, 2025
Maintains: Outperform
Price Target: $20 → $12
Current: $12.98
Upside: -7.55%
Alnylam Pharmaceuticals
Sep 11, 2025
Maintains: Outperform
Price Target: $280 → $515
Current: $354.75
Upside: +45.19%
Savara
May 28, 2025
Maintains: In-Line
Price Target: $3 → $2
Current: $5.85
Upside: -65.81%
CRISPR Therapeutics AG
Feb 14, 2025
Upgrades: Outperform
Price Target: $60 → $99
Current: $54.26
Upside: +82.45%
Travere Therapeutics
Feb 12, 2025
Maintains: Outperform
Price Target: $33 → $45
Current: $30.03
Upside: +49.85%
BioCryst Pharmaceuticals
Jan 13, 2025
Maintains: Outperform
Price Target: $10 → $12
Current: $6.76
Upside: +77.51%
Editas Medicine
Dec 16, 2024
Maintains: Outperform
Price Target: $7 → $5
Current: $2.11
Upside: +136.97%
Kiniksa Pharmaceuticals International,
Oct 30, 2024
Maintains: Outperform
Price Target: $30 → $35
Current: $44.64
Upside: -21.59%
Madrigal Pharmaceuticals
Aug 8, 2024
Maintains: Outperform
Price Target: $405 → $360
Current: $500.39
Upside: -28.06%
May 16, 2024
Maintains: In-Line
Price Target: $7 → $2
Current: $1.21
Upside: +65.98%
Jun 6, 2023
Upgrades: Outperform
Price Target: $60 → $80
Current: $24.62
Upside: +224.94%
Jan 18, 2023
Maintains: Outperform
Price Target: $14 → $25
Current: $6.18
Upside: +304.53%
Nov 23, 2021
Initiates: Outperform
Price Target: $35
Current: $5.66
Upside: +518.37%
Jun 8, 2021
Initiates: Outperform
Price Target: $24
Current: $46.75
Upside: -48.66%
Nov 24, 2020
Reinstates: Outperform
Price Target: $30
Current: $19.82
Upside: +51.36%
Feb 5, 2020
Upgrades: Market Outperform
Price Target: $10
Current: $4.16
Upside: +140.38%